Salt Lake City, UT Clinical Trials Report — May 2026

For Salt Lake City residents considering participation in clinical research, May 2026 offers both urgent opportunities and exciting new avenues to contribute to medical science. Across the city, a significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 44 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 2 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers, neurological conditions, and respiratory issues are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Acute lymphoblastic leukemia (2 trials)
• Advanced NSCLC (1 trial)
• ALS - Amyotrophic lateral sclerosis (1 trial)
• Acute undifferentiated leukemia (1 trial)
• Brain injuries, traumatic (1 trial)
• Advanced solid tumor (1 trial)
• Acute myeloid leukemia (1 trial)
• Asthma (1 trial)
• Astrocytoma (1 trial)
• Astrocytoma, IDH-mutant (1 trial)

New Research Opportunities Emerge in Salt Lake City

This month, Salt Lake City saw the opening of 17 new clinical trials, a slight increase from the 16 trials that launched in March 2026. This brings the total number of actively recruiting clinical trials in Salt Lake City, UT, to 877 across 257 research facilities, underscoring the city's robust research landscape. This trend of new trials remains strong, with May's 17 new studies aligning with the average of the past 6 months.

May brings several high-profile new trials to Salt Lake City, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial aims for 2,500 participants to evaluate the safety and effectiveness of CagriSema for body weight loss in individuals with obesity, with or without type 2 diabetes.
• AstraZeneca is sponsoring NCT07611110, "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)," a Phase 3 study involving 670 participants. The study intends to demonstrate the superiority of AZD2265 relative to standard of care treatments by assessing radiographic progression-free survival and overall survival in participants with metastatic castration-resistant prostate cancer.
• The University of Utah is leading NCT07599943, "Population Health Management -Increase Lung Cancer Screening in Community Health Centers (LungSMART)," an initiative aiming for 18,894 participants. The long-term goal is to increase the reach of Low-Dose Computed Tomography (LDCT) screening for lung cancer in low-resource healthcare settings.
• Another significant study from the University of Utah is NCT07582016, "Partnership to Reduce Obesity in Community Health Center Patients (SMARTLife Utah)," targeting 5,354 participants. This study seeks to increase the reach of existing digital evidence-based interventions for obesity among patients of Community Health Centers.
• The Duchenne Registry is sponsoring NCT07609394, "Duchenne Electronic Health Record Study," aiming for 2,500 participants. This study collects retrospective and prospective, long-term data of patients with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic transfer from consented patients' electronic health records.
• The University of Utah is also behind NCT07586917, "Optimizing Pregnancy and Treatment Interventions for Moms 3.0," involving 429 participants. This research aims to determine if Patient Navigation helps pregnant Medicaid members with opioid use disorder, with or without stimulant use disorder, stay in care, use medications for opioid use disorder, reduce substance use, and connect with services.

New trials this month are exploring a range of conditions, with the most frequent being obesity (2 trials), followed by Becker muscular dystrophy (1 trial), congenital heart disease (1 trial), and Duchenne muscular dystrophy (1 trial). Drug trials account for the largest share of new studies, with 7 new drug trials, followed by 6 behavioral trials and 3 other types of studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 17 new trials launched this month, 3 are actively seeking healthy volunteers. Across Salt Lake City, a total of 74 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Salt Lake City's Leading Research Facilities

Salt Lake City is home to some of Utah's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Utah (188 trials)
• Huntsman Cancer Institute/University of Utah (85 trials)
• Primary Children's Hospital (65 trials)
• Huntsman Cancer Institute (63 trials)
• Huntsman Cancer Institute, University of Utah (30 trials)
• University of Utah Health (23 trials)
• LDS Hospital (19 trials)
• University of Utah Sugarhouse Health Center (18 trials)
• Huntsman Cancer Institute at University of Utah (18 trials)
• Research Site (17 trials)
• University of Utah Hospital (14 trials)
• Huntsman Cancer Institute at the University of Utah (13 trials)

These institutions, particularly the various University of Utah and Huntsman Cancer Institute locations, offer a broad spectrum of research, from oncology and pediatric care to general health and specialized medical fields.

Broadening Your Search: Nearby Options

While Salt Lake City offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Utah. Cities with active trials include Murray (2 trials), Sandy City (2 trials), Draper (1 trial), Millcreek (1 trial), Orem (1 trial), and South Jordan (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 17 new trials launched this month, 15 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children, 1 is female-only, and 1 is male-only. Academic institutions continue to play a vital role in Salt Lake City's research ecosystem, with the University of Utah sponsoring the most new studies (9 trials). Industry sponsors like AstraZeneca (2 trials) and Novo Nordisk A/S (1 trial) are also driving significant research efforts.

As we move further into spring, Salt Lake City's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.